There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inovio Pharmaceuticals (INO) and Leap Therapeutics Inc (LPTX) with bullish sentiments.
Inovio Pharmaceuticals (INO)
In a report released today, Ram Selvaraju from H.C. Wainwright initiated coverage with a Buy rating on Inovio Pharmaceuticals and a price target of $13. The company’s shares closed yesterday at $3.49, close to its 52-week low of $3.02.
Selvaraju wrote:
“We note that ASF is highly contagious and the hemorrhagic viral disease is lethal and incurable in domestic and wild pigs. Within the past year, the ASF virus has spread from Europe to Asia countries, including China, Vietnam and Korea. Specifically, over 1M pigs have been culled and slaughtered in 2018, resulting in substantial economic losses. In our view, this partnership could bring Inovio additional upside in the animal health sector without any financial burden. In the wake of this update, we reiterate our Buy rating and $13 price target.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -1.8% and a 34.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Inovio Pharmaceuticals is a Strong Buy with an average price target of $10.50, implying a 200.9% upside from current levels. In a report issued on May 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
Leap Therapeutics Inc (LPTX)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Leap Therapeutics Inc today and set a price target of $10. The company’s shares closed yesterday at $1.54, close to its 52-week low of $1.35.
Ramakanth noted:
“We maintain our Buy rating of LPTX and our 12-month price target to $10.00 per diluted share. We derive our price target based on a risk-adjusted NPV (rNPV) analysis of projected DKN-01 and TRX518 revenues through 2030 assuming a 12% discount rate and a 2% terminal growth rate.”
According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.2% and a 31.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, Gritstone Oncology Inc, and IntelGenx Technologies.
Currently, the analyst consensus on Leap Therapeutics Inc is a Moderate Buy with an average price target of $10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
